Enliven Therapeutics, Inc.
ELVN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.99 | 0.10 | -0.03 | 0.11 |
| FCF Yield | -6.91% | -12.48% | -31.97% | -27.48% |
| EV / EBITDA | -10.57 | -4.79 | -0.70 | 1.60 |
| Quality | ||||
| ROIC | -33.66% | -33.87% | -49.56% | -22.93% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.82 | 0.86 | 0.85 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -19.24% | -87.89% | -69.15% | -114.96% |
| Safety | ||||
| Net Debt / EBITDA | 1.40 | 1.22 | 1.95 | 4.46 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,545.21 | -653.80 | -2,017.48 | -9,294.60 |